 Connection
Pamela Peterson to Ventricular Dysfunction, Left
This is a "connection" page, showing publications Pamela Peterson has written about Ventricular Dysfunction, Left.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.173 |
|
|
|
-
Borne RT, Masoudi FA, Curtis JP, Zipse MM, Sandhu A, Hsu JC, Peterson PN. Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. JAMA Netw Open. 2021 01 04; 4(1):e2035470.
Score: 0.573
-
Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes. 2010 May; 3(3):309-15.
Score: 0.272
-
Pierce JB, Blumer V, Choi S, Hardy NC, Greiner MA, Carnicelli AP, Shen X, Lippmann SJ, Peterson PN, Allen LA, Fonarow GC, Mentz RJ, Greene SJ, O'Brien EC. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Na?ve to Renin-Angiotensin System Inhibitors. Am J Cardiol. 2023 10 01; 204:151-158.
Score: 0.171
-
Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, DeVore AD, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Linganathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Greene SJ. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023 07 01; 8(7):652-661.
Score: 0.170
-
Swat SA, Xu H, Allen LA, Greene SJ, DeVore AD, Matsouaka RA, Goyal P, Peterson PN, Hernandez AF, Krumholz HM, Yancy CW, Fonarow GC, Hess PL. Opportunities and Achievement of Medication Initiation Among Inpatients With Heart?Failure With Reduced Ejection?Fraction. JACC Heart Fail. 2023 08; 11(8 Pt 1):918-929.
Score: 0.170
-
Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Mcdermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2022 04; 28(4):554-563.
Score: 0.152
-
Sandhu A, Bao H, Minges KE, Varosy PD, Borne RT, Zipse MM, Marzec L, Peterson P, Masoudi F, Bradley SM. Use of Cardiac Resynchronization Therapy Defibrillator in US Hospitals. JAMA Cardiol. 2019 08 01; 4(8):804-809.
Score: 0.130
-
Hajduk AM, Gurwitz JH, Tabada G, Masoudi FA, Magid DJ, Greenlee RT, Sung SH, Cassidy-Bushrow AE, Liu TI, Reynolds K, Smith DH, Fiocchi F, Goldberg R, Gill TM, Gupta N, Peterson PN, Schuger C, Vidaillet H, Hammill SC, Allore H, Go AS. Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies. J Am Geriatr Soc. 2019 07; 67(7):1370-1378.
Score: 0.127
-
Greenlee RT, Go AS, Peterson PN, Cassidy-Bushrow AE, Gaber C, Garcia-Montilla R, Glenn KA, Gupta N, Gurwitz JH, Hammill SC, Hayes JJ, Kadish A, Magid DJ, McManus DD, Multerer D, Powers JD, Reifler LM, Reynolds K, Schuger C, Sharma PP, Smith DH, Suits M, Sung SH, Varosy PD, Vidaillet HJ, Masoudi FA. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network. J Am Heart Assoc. 2018 03 26; 7(7).
Score: 0.118
-
Masoudi FA, Mi X, Curtis LH, Peterson PN, Curtis JP, Fonarow GC, Hammill SC, Heidenreich PA, Al-Khatib SM, Piccini JP, Qualls LG, Hernandez AF. Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. Ann Intern Med. 2014 May 06; 160(9):603-11.
Score: 0.090
-
Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen LA, Masoudi FA. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013 Mar; 6(2):166-73.
Score: 0.083
-
Masoudi FA, Go AS, Magid DJ, Cassidy-Bushrow AE, Doris JM, Fiocchi F, Garcia-Montilla R, Glenn KA, Goldberg RJ, Gupta N, Gurwitz JH, Hammill SC, Hayes JJ, Jackson N, Kadish A, Lauer M, Miller AW, Multerer D, Peterson PN, Reifler LM, Reynolds K, Saczynski JS, Schuger C, Sharma PP, Smith DH, Suits M, Sung SH, Varosy PD, Vidaillet HJ, Greenlee RT. Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice. Circ Cardiovasc Qual Outcomes. 2012 Nov; 5(6):e78-85.
Score: 0.081
-
Venechuk GE, Khazanie P, Page RL, Knoepke CE, Helmkamp LJ, Peterson PN, Pierce K, Thompson JS, Huang J, Strader JR, Dow TJ, Richards L, Trinkley KE, Kao DP, McIlvennan CK, Magid DJ, Buttrick PM, Matlock DD, Allen LA. An Electronically delivered, Patient-activation tool for Intensification of medications for Chronic Heart Failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial. Am Heart J. 2020 11; 229:144-155.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|